Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0PZICY |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | SYM004 (anti-DLL3) |
|||||
| Organization | CSPC MEGALITH BIOPHARMACEUTICAL CO.,LTD. |
|||||
| Synonyms |
SYM004 (anti-DLL3)
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Delta-like protein 3 (DLL3) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTY
ADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARIGDSSPSDYWGQGTLVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPG Click to Show/Hide
|
|||||
| Light Chain Sequence |
EIVMTQSPATLSVSPGERATLSCKASQSVSNDVVWYQQKPGQAPRLLIYYASNRYTGIPA
RFSGSGSGTEFTLTISSLQSEDFAVYYCQQDYTSPWTFGQGTKLEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
wO2024169913A1 ADC04-02-8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.0227 nM
|
High DLL3 expression (DLL3+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H82 cells
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H82 cells | CVCL_1591 | ||
wO2024169913A1 ADC04-07-8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.04488 nM
|
High DLL3 expression (DLL3+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H82 cells
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H82 cells | CVCL_1591 | ||
wO2024169913A1 ADC04-01-8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.06064 nM
|
High DLL3 expression (DLL3+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H82 cells
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H82 cells | CVCL_1591 | ||
wO2024169913A1 ADC04-08-8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.118 nM
|
High DLL3 expression (DLL3+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H82 cells
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H82 cells | CVCL_1591 | ||
wO2024169913A1 ADC04-09-8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.2235 nM
|
High DLL3 expression (DLL3+++) | ||
| Method Description |
Cytotoxicity of ADC to NCI-H82 cells
|
||||
| In Vitro Model | Lung small cell carcinoma | NCI-H82 cells | CVCL_1591 | ||